Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials

Nadine Kronfli; Matthew J. Akiyama

doi:10.1016/j.eclinm.2020.100659

Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials

Nadine Kronfli, Matthew J. Akiyama

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

13 Scopus citations

Original language	English (US)
Article number	100659
Journal	EClinicalMedicine
Volume	31
DOIs	https://doi.org/10.1016/j.eclinm.2020.100659
State	Published - Jan 2021

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eclinm.2020.100659

Cite this

@article{b67f6a798e5b43318e9b38f6eb953cb8,

title = "Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials",

author = "Nadine Kronfli and Akiyama, {Matthew J.}",

note = "Funding Information: NK is supported by a career award from the Fonds de Recherche Qu{\'e}bec – Sant{\'e} (FRQ-S; Junior 1). MJA is supported by a grant from NIH/NIDA R00 DA043011 . Funding Information: NK is supported by a career award from the Fonds de Recherche Qu?bec ? Sant? (FRQ-S; Junior 1). MJA is supported by a grant from NIH/NIDA R00 DA043011. Funding Information: NK has received research funding from Gilead Sciences, advisory fees from Gilead Sciences, ViiV Healthcare, Merck and Abbvie, and speaker fees from Gilead Sciences. MJA has no conflicts of interest. ",

year = "2021",

month = jan,

doi = "10.1016/j.eclinm.2020.100659",

language = "English (US)",

volume = "31",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials

AU - Kronfli, Nadine

AU - Akiyama, Matthew J.

N1 - Funding Information: NK is supported by a career award from the Fonds de Recherche Québec – Santé (FRQ-S; Junior 1). MJA is supported by a grant from NIH/NIDA R00 DA043011 . Funding Information: NK is supported by a career award from the Fonds de Recherche Qu?bec ? Sant? (FRQ-S; Junior 1). MJA is supported by a grant from NIH/NIDA R00 DA043011. Funding Information: NK has received research funding from Gilead Sciences, advisory fees from Gilead Sciences, ViiV Healthcare, Merck and Abbvie, and speaker fees from Gilead Sciences. MJA has no conflicts of interest.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85098753946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098753946&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2020.100659

DO - 10.1016/j.eclinm.2020.100659

M3 - Comment/debate

AN - SCOPUS:85098753946

SN - 2589-5370

VL - 31

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 100659

ER -

Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this